Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply

We thank Kirti Singh and colleagues for their interest in the CHART study. Several studies showed superior clinical benefit with bicalutamide plus androgen-deprivation therapy than with androgen-deprivation therapy alone.1 In addition, bicalutamide plus androgen-deprivation therapy was recommended both in National Comprehensive Cancer Network and in Chinese Society of Clinical Oncology guidelines. In some countries, such as China and Japan, bicalutamide plus androgen-deprivation therapy is administered in clinical practice for the management of metastatic hormone-sensitive prostate cancer.